You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Obesity

Setmelanotide for treating obesity caused by LEPR or POMC deficiency

  • Highly specialised technologies guidance
  • Reference number: HST21
  • Published:  06 July 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Case studies
  2. Guidance into practice

Tools and resources

Tools and resources to help you put the guidance into practice.

Case studies

  • Injectable anti-obesity medications in specialist weight management services: supporting people with complex needs

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top